BMS 986177

Drug Profile

BMS 986177

Alternative Names: BMS-986177

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antithrombotics
  • Mechanism of Action Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 31 Jan 2017 Bristol-Myers Squibb withdraws a phase I pharmacokinetics trial prior to enrolment in USA (NCT02982707)
  • 20 Dec 2016 Bristol-Myers Squibb plans a phase I/II trial for Thrombosis in USA (PO) (NCT03000673)
  • 01 Dec 2016 Bristol-Myers Squibb completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02959060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top